Pemetrexed (Alimta)
A Meta-Analysis of First-Line Treatments for Unresectable Pleural Mesothelioma: Indirect Comparisons from Reconstructed Individual Patient Data of Six Randomized Controlled Trials
Cancers 2025 February 3 [Link] Andrea Messori, Sabrina Trippoli, Eugenia Piragine, Sara Veneziano, Vincenzo Calderone Abstract Background: In unresectable pleural mesothelioma, pemetrexed+cisplatin as first line is considered the standard of care, but novel treatments have been recently proposed. Methods: Our objective was to compare, albeit indirectly, the results of randomized controlled trials on overall survival…
Read MoreTumor Treating Fields enhance chemotherapy efficacy by increasing cellular drug uptake and retention in mesothelioma cells
American Journal of Cancer Research 2025 January 15 [Link] Rosy Amodeo, Lavinia Morosi, Marina Meroni, Ezia Bello, Sara Timo, Roberta Frapolli, Maurizio D’Incalci, Monica Lupi Abstract Tumor Treating Fields (TTFields) applied with standard chemotherapy have been approved for the first-line treatment of unresectable pleural mesothelioma (PM), an aggressive malignancy with limited effective therapy options. In…
Read MoreLong-term survival from multidisciplinary treatment of primary malignant pericardial mesothelioma: A case report
International Journal of Surgery Case Reports 2024 December [Link] Vu Anh Hai, Nghiem Thi Minh Chau, Ho Viet Hoanh, Ha Van Tri, Dinh Cong Pho, Nguyen Van Nam Abstract Introduction and importance: Primary malignant pericardial mesothelioma is an extremely rare disease with a poor prognosis. Currently, there are no specific guidelines for diagnosis and treatment…
Read MoreNOTCH and PTP4A3 alterations emerge as novel predictive biomarkers and potential therapeutic targets in pleural mesothelioma
Lung Cancer 2024 December [Link] Mariacarmela Santarpia, Marta Aliprandi, Calogera Claudia Spagnolo, Amir Avan, Rafael Rosell, Paolo Andrea Zucali, Elisa Giovannetti Abstract Background: Previous studies showed opposite effects of NOTCH1 and NOTCH2 on mesothelioma cell survival under hypoxia. Mechanisms underlying these effects are not still clear and this pathway plays a key role in angiogenesis…
Read MoreThe impact of Charcot-Leyden Crystal protein on mesothelioma chemotherapy: targeting eosinophils for enhanced chemosensitivity
EBioMedicine 2024 November [Link] Mégane Willems, Malik Hamaidia, Alexis Fontaine, Mélanie Grégoire, Louise Halkin, Lea Vilanova Mañá, Roxane Terres, Majeed Jamakhani, Sophie Deshayes, Yves Brostaux, Vincent Heinen, Renaud Louis, Bernard Duysinx, Didier Jean, Eric Wasielewski, Arnaud Scherpereel, Christophe Blanquart, Luc Willems Abstract Background: In mesothelioma (MPM), clinical evidence indicates that the absolute eosinophil count negatively…
Read MoreComparison of First-Line Chemotherapeutics and Validation of the EORTC Prognostic Index in Malignant Pleural Mesothelioma: Retrospective Single-Centre Experience
Journal of the College of Physicians and Surgeons 2024 August [Link] Yasin Sezgin, Ogur Karhan, Serdar Ileri, Senar Ebinc, Sezai Tunc, Zuhat Urakci Abstract Objective: To evaluate the efficiency of pemetrexed cisplatin in comparison with gemcitabine cisplatin and to validate the EORTC (European Organisation for Research and Treatment of Cancer) prognostic score in combination chemotherapy…
Read MoreChemotherapy increases CDA expression and sensitizes malignant pleural mesothelioma cells to capecitabine treatment
Scientific Reports 2024 August 6 [Link] Darya Karatkevich, Tereza Losmanova, Philipp Zens, Haibin Deng, Christelle Dubey, Tuo Zhang, Corsin Casty, Yanyun Gao, Christina Neppl, Sabina Berezowska, Wenxiang Wang, Ren-Wang Peng, Ralph Alexander Schmid, Patrick Dorn, Thomas Michael Marti Abstract The combination of cisplatin and pemetrexed remains the gold standard chemotherapy for malignant pleural mesothelioma (MPM),…
Read MoreContemporary management of mesothelioma
Breathe 2024 July 16 [Link] Mark D J Neilly, Jennifer Pearson, Akari Win Thu, Carolyn MacRae, Kevin G Blyth Abstract Pleural mesothelioma (PM) is an aggressive asbestos-associated thoracic malignancy with a median survival of 12-18 months. Due to continued asbestos use in many nations, global incidence is rising. Causes due to non-occupational, environmental exposure are…
Read MoreIntegration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma-Protocol of the Immuno-MESODEC study
PloS One 2024 July 15 [Link] Jolien Van den Bossche, Maxime De Laere, Koen Deschepper, Paul Germonpré, Yvan Valcke, Jan Lamont, Barbara Stein, Kirsten Van Camp, Charlotte Germonpré, Griet Nijs, Ella Roelant, Sébastien Anguille, Eva Lion, Zwi Berneman Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer with a very poor prognosis. Recently, immune checkpoint…
Read MoreReal-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04-2021) trial
Lung Cancer 2024 June 29 [Link] Olivier Bylicki, Florian Guisier, Arnaud Scherpereel, Catherine Daniel, Aurélie Swalduz, Emmanuel Grolleau, Marie Bernardi, Stephane Hominal, Jean Briac Prevost, Guillaume Pamart, Marie Héléne Marques, Nicolas Cloarec, Simon Deshayes, Judith Raimbourg, Rémi Veillon, Youssef Oulkhouir, Clarisse Audigier Valette, Fabien Subtil, Christos Chouaïd, Laurent Greillier Abstract Background: First-line standard-of-care for unresectable,…
Read More